MedTrace Logo

A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease

NCT04520412 · Status: SUSPENDED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2046

Last updated 2022-11-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of GV-971 in mild to moderate Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

GV-971

Administered PO

DRUG

Placebo

Administered PO

Sponsors & Collaborators

  • Green Valley (Shanghai) Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Study Director, Ph D · Green Valley (Shanghai) Pharmaceuticals Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-27
Primary Completion
2025-12-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • China
  • Czechia
  • France
  • Hong Kong
  • Netherlands
  • Poland
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04520412 on ClinicalTrials.gov